BCAX — Bicara Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2023658 ·
Last close
$17.26
Market Cap
$1.14B
52W High
$30.99
52W Low
$13.70
ADV30
672,262
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -59,951,000 | -55,436,000 | 512,243,000 | 96,599,000 | 43,475,000 |
| Mar 2026 | 0 | — | -60,242,000 | -56,211,000 | 553,599,000 | 323,462,000 | 39,641,000 |
| Dec 2025 | 0 | — | -41,122,000 | -37,386,000 | 430,994,000 | 96,685,000 | 29,542,000 |
| Sep 2025 | 0 | — | -40,676,000 | -36,330,000 | 424,688,000 | 171,673,000 | 21,908,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-116,236,000
Investing CF
$-217,513,000
Financing CF
$195,146,000
CapEx
$-338,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.78
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-415,177,000
Inventory
—
Receivables
—
ST Investments
$216,291,000
EBIT TTM
$-174,058,000
Pretax Income TTM
$-157,118,000
Interest Exp TTM
—
Analysts
13
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -155,604,000 | -137,950,000 | 430,994,000 | 29,542,000 | 401,452,000 | -106,834,000 |
| Dec 2024 | 0 | -82,389,000 | -67,995,000 | 509,996,000 | 18,121,000 | 491,875,000 | -74,751,000 |
| Dec 2023 | 0 | -39,889,000 | -51,985,000 | 233,982,000 | 382,751,000 | -148,769,000 | -45,628,000 |
| Dec 2022 | 0 | -37,656,000 | -37,845,000 | 6,703,000 | 105,506,000 | -98,803,000 | -32,076,000 |
TTM Snapshot
Revenues TTM
$16,940,000
NetIncome TTM
$-157,315,000
OpCashFlow TTM
—
Assets (Latest)
$553,599,000
Forward EPS
$-3.47
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TRAX | First Tracks Biotherapeutics, Inc. | $1.14B | $32.01 | — |
| AVLN | Avalyn Pharma Inc. | $1.14B | $25.72 | — |
| HROW | HARROW, INC. | $1.14B | $30.52 | — |
| JANX | Janux Therapeutics, Inc. | $1.13B | $18.50 | — |
| NBTX | Nanobiotix S.A. | $1.16B | $22.90 | — |
News headlines (Yahoo Finance, 1h cache)
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-09-03 12:30 · Yahoo
Bicara Therapeutics (BCAX) Q2 2026 Earnings Call Transcript
2026-08-18 15:13 · Yahoo
Bicara Therapeutics' Cancer Study On Track for 2026 Enrollment, Wedbush Says
2026-08-11 17:28 · Yahoo
Bicara Therapeutics stock gains 3% as pivotal trial enrollment advances
2026-08-11 14:17 · Yahoo
Bicara Therapeutics Q2 Earnings Call Highlights
2026-08-11 14:04 · Yahoo
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?
2026-06-13 05:21 · Yahoo
Bicara (BCAX) Q4 2025 Earnings Transcript
2026-06-01 16:13 · Yahoo
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer
2026-05-22 15:09 · Yahoo
Bicara Therapeutics Inc. Common Stock Q2 2026 Earnings Call Summary
2026-08-11 17:15 · Yahoo
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-10-05 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.